SMC accepts venetoclax for untreated chronic lymphocytic leukaemia

Venetoclax is accepted for restricted use within NHS Scotland in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

Please sign in or register for FREE

No comments yet.